Key terms
About VXRT
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VXRT news
Apr 30
8:38am ET
Vaxart announces results for bivalent norovirus vaccine candidate
Mar 20
8:11am ET
Vaxart reports inducement grants under Nasdaq listing rule
Mar 20
7:25am ET
Buy Rating Affirmed for Vaxart Amid Promising Vaccine Trials and Strategic Advancements
Mar 14
8:05am ET
Options Volatility and Implied Earnings Moves Today, March 14, 2024
Mar 11
8:00am ET
Options Volatility and Implied Earnings Moves This Week, March 11 – March 15, 2024
Mar 06
9:32am ET
Vaxart Inc Welcomes Steven Lo as New CEO and President
Mar 06
8:07am ET
Vaxart appoints Steven Lo as President, CEO, Director
Feb 29
4:43pm ET
Vaxart Inc Launches New Equity Plan to Attract Talent
Feb 23
11:04am ET
Biotech Alert: Searches spiking for these stocks today
Feb 15
4:23pm ET
Vaxart Regains Compliance with Nasdaq Listing Standards
Feb 05
8:13am ET
Vaxart announces publication of preclinical data on vaccine candidates
Feb 02
11:07am ET
Biotech Alert: Searches spiking for these stocks today
No recent press releases are available for VXRT
VXRT Financials
Key terms
Ad Feedback
VXRT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VXRT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
